Moderator: David Shlaes, Anti-infectives consulting, retired
- Ian Friedland, Clinical consultant, Friedland Strategic Consulting, LLC
- Sumathi Nambiar, Director, Division of Anti-Infective Products, Office of Antimicrobial Products, CDER, FDA
- Mair Powell, Senior Clinical Assessor, Health Products Regulatory Authority (Ireland)
The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products. Our first webinar was devoted to more traditional approaches (Tiers A and B), best suited for more broad-spectrum products, where the risks are lower. In the second webinar, we discussed the development of products that target a single species of bacteria where the risks may be higher. In this third webinar, we will discuss the development of antibacterial drug enhancer combinations and non-traditional products.
Register here for this live webinar including interactive Q&A session on 28 March 2019, 17:00-18:30 (CET).